Reumatología
Servicio
University of Copenhagen
Copenhague, DinamarcaPublicaciones en colaboración con investigadores/as de University of Copenhagen (23)
2024
2022
-
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Annals of the rheumatic diseases, Vol. 81, Núm. 6, pp. 768-779
-
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Rheumatology (Oxford, England), Vol. 61, Núm. 9, pp. 3799-3807
-
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Arthritis Care and Research, Vol. 74, Núm. 7, pp. 1205-1218
-
The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis
Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4741-4751
2021
-
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
Annals of the Rheumatic Diseases, Vol. 80, Núm. 10, pp. 1278-1285
-
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
Annals of the Rheumatic Diseases, Vol. 80, Núm. 11, pp. 1410-1418
-
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
Frontiers in Immunology, Vol. 12
2020
-
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
RMD open, Vol. 6, Núm. 3
-
Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis
Rheumatology (United Kingdom), Vol. 59, Núm. 9, pp. 2455-2461
-
NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium
Scientific Reports, Vol. 10, Núm. 1
2019
-
A Phase II Trial of Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis
Arthritis and Rheumatology, Vol. 71, Núm. 7, pp. 1056-1069
-
Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients (The Pharmacogenomics Journal, (2019), 19, 1, (83-96), 10.1038/s41397-018-0057-x)
Pharmacogenomics Journal
-
Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients
Pharmacogenomics Journal, Vol. 19, Núm. 1, pp. 83-96
-
Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1536-1544
2018
-
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
Annals of the Rheumatic Diseases, Vol. 77, Núm. 4, pp. 476-479
2017
-
Rituximab retreatment in rheumatoid arthritis in a real-life cohort: Data from the CERERRA collaboration
Journal of Rheumatology, Vol. 44, Núm. 2, pp. 162-169
-
Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies
Annals of the Rheumatic Diseases, Vol. 76, Núm. 11, pp. 1870-1882
2016
-
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 3-15